The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -2.38 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as IMPACT BIOMEDICAL INC. reports it. History and quarterly detail are in the app.
- Biotech Retail Sales$32K
Leadership changes
From IMPACT BIOMEDICAL INC.'s own filings, the day they're filed.
- Chan Heng Fai Ambrose · Director · appointmenteff. 2025-03-11
- Jason T. Grady · Director · appointmenteff. 2024-06-06
- Heng Fai Ambrose Chan · member · departureeff. 2024-06-06
Latest filings
- 10-Q · Quarterly report2026-05-12
- 10-K · Annual report2026-03-11
- 8-K · Company announcement2026-03-04
- 10-Q · Quarterly report2025-11-07
- 8-K · Company announcement2025-11-06
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about IMPACT BIOMEDICAL INC., every answer cited🔒
- The Intelligence Brief — added when IMPACT BIOMEDICAL INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.